Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (141 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartfailuredlcongestiveventricular
  Phrases that lowered it: screeningthe studydoses offemaleallergy
• Design: crossover (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 118 (lowers risk) · Sponsor's track record
• Responsible party: not given (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: basic science (raises risk) · Design
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 10.5% (lowers risk) · Drug's FDA history
• Blinding: triple (raises risk) · Design
• Maximum age: 90 (lowers risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past termination rate: 7.3% (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 164 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Low Dose Intravenous (IV) Infusion of BNP in the Presence and Absence of Acute Type V Phosphodiesterase (PDE V) in Improving Renal Function in Hospitalized Chronic Heart Failure (CHF) Patients With Renal Dysfunction NCT00972569 · started 2009 · scored riskier than 71% of active trials completed
• CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function NCT01678794 · started 2012 · scored riskier than 77% of active trials completed
• The Effects of Decreasing the Lasix Dose on the Cardiorenal System NCT00982423 · started 2009 · scored riskier than 80% of active trials completed
• Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study NCT01132846 · started 2010 · scored riskier than 93% of active trials completed
• CD-NP in Subjects With Stable Chronic Heart Failure NCT00620308 · started 2008 · scored riskier than 60% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.